Teacher Retirement System of Texas cut its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 33.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,372 shares of the company’s stock after selling 19,628 shares during the period. Teacher Retirement System of Texas’ holdings in TherapeuticsMD were worth $187,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. MANA Advisors LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $104,000. Paloma Partners Management Co acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $105,000. Trellus Management Company LLC acquired a new stake in shares of TherapeuticsMD during the first quarter worth $317,000. MetLife Investment Advisors LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $423,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of TherapeuticsMD during the first quarter worth $455,000. 72.70% of the stock is currently owned by institutional investors.
Shares of TherapeuticsMD opened at $6.99 on Wednesday, MarketBeat.com reports. TherapeuticsMD Inc has a 1-year low of $4.34 and a 1-year high of $7.66. The firm has a market cap of $1.52 billion, a PE ratio of -18.89 and a beta of 1.34.
TXMD has been the topic of a number of recent analyst reports. ValuEngine raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. Oppenheimer reaffirmed a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, March 21st. Zacks Investment Research lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, April 25th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a report on Friday, March 9th. Finally, JPMorgan Chase & Co. started coverage on TherapeuticsMD in a report on Friday, June 15th. They set an “overweight” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average price target of $14.63.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.